Skip to content

D&A at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$6.84M+28.3%
ADMA Biologics logo
ADMA BiologicsADMA
$1.8M-5.3%
Xencor logo
XencorXNCR
$2.57M-4.7%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.4%
Zymeworks logo
ZymeworksZYME
$176K-89.1%
XER
Xeris Biopharma Holdings, Inc.XERS
$2.71M0.0%

Segments

By segment

See full
Segment One$2.73M-11.2%

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Cash & equivalents$9.7M-84.9%
Total debt$4.0M-37.2%
Total equity$172.0M-13.5%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.57B+341%
Enterprise value$1.57B+425%
P/S855.5×+782×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Absci Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Absci Corporation's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Absci Corporation's D&A?
Absci Corporation (ABSI) reported D&A of $2.73M in Q1 2026.
How has Absci Corporation's D&A changed year-over-year?
Absci Corporation's D&A decreased by 11.2% year-over-year, from $3.07M to $2.73M.
What is the long-term trend for Absci Corporation's D&A?
Over 4 years (2021 to 2025), Absci Corporation's D&A has grown at a 15.3% compound annual growth rate (CAGR), from $6.65M to $11.74M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.